Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer

Takashi Nomizo(Takatsuki Red Cross Hospital), Hideo Kita(Takatsuki Red Cross Hospital), Mami Sonomura(Takatsuki Red Cross Hospital), Naoki Kanda(Jichi Medical University), Yasukiyo Nakamura(Takatsuki Red Cross Hospital), Hiroko Fukata(Takatsuki Red Cross Hospital), Haruka Yamamoto(Takatsuki Red Cross Hospital), Chihiro Watanabe(International Institute for Applied Systems Analysis), Aika Okuno(Takatsuki Red Cross Hospital), Tsunetaka Murayama(Takatsuki Red Cross Hospital)
Trends in Immunotherapy
January 14, 2022
Cited by 1


Related Papers